Laparoscopic Gastric Band With Active Agents

• US 20100280310A1
• Filed: 04/30/2010
• Published: 11/04/2010
• Est. Priority Date: 05/01/2009
• Status: Abandoned Application

• Current Assignee: Apollo Endosurgery, Inc. (Boston Scientific Corporation)
• Original Assignee: Allergan, Inc. (Canada) (Abbvie Incorporated)
• Inventors: Raven, Joseph S.
• Application Number:
  US12/771,671
• Publication Number:
  US 20100280310A1
• Time in Patent Office: Days
• US Class Current: 600/37
• CPC Class Codes: A61F 5/0056 using injection ports
• CPC Class Codes: A61L 31/16 Biologically active materials, e.g. therapeutic substances A61L31/047 takes precedence

Abstract

A gastric banding system is provided which generally includes a gastric band and an active agent, for example, a metabolic agent or satiety inducing agent. The band may be structured to contain the agent and permit controlled release of the agent to the patient while the band is positioned around the stomach. Methods for treating obesity are also provided which include positioning a gastric band on the stomach of a patient and administering a satiety inducing agent to the patient while the gastric band is positioned on the stomach.

Claims

1. A gastric banding system comprising:

a gastric band structured to be placed around the stomach of a patient and the band being structured to be capable of dispensing an active agent to the patient while the band is positioned around the stomach.

2. The system of claim 1 further comprising an active agent for being dispensed to the patient while the band is positioned around the stomach.

3. The system of claim 1 further comprising a satiety inducing agent incorporated into the gastric band.

4. The system of claim 3 wherein the satiety inducing agent is a hormone.

5. The system of claim 3 wherein the satiety inducing agent is a peptide hormone.

6. The system of claim 5 wherein the peptide hormone is an agent selected from the group consisting of Glucagon-like peptide (GLP-1), Oxyntomodulin (OXM), Peptide YY (PYY), Pancreatic Polypeptide (PP), Insulin, Leptin, Gastrin, Ghrelin blocker, an inhibitors of DPP-IV, and Amylin.

7. The system of claim 3 wherein the satiety inducing agent is Cholecystokinin (CCK).

8. The system of claim 1 further comprising an ancillary device incorporated into the gastric band and capable of dispensing an active agent to the patient.

9. The system of claim 8 wherein the ancillary device is structured to provide controlled release of an active agent to the patient.

10. The system of claim 8 wherein the ancillary device comprises a membrane or film permeable to an active agent.

11. The system of claim 8 wherein the ancillary device includes grooves capable of containing an active agent.

12. The system of claim 8 wherein the ancillary device includes pores capable of containing an active agent.

13. The system of claim 8 wherein the ancillary device includes an active agent.

14. The system of claim 13 wherein the active agent is a satiety inducing agent.

15. The system of claim 13 wherein the ancillary device further includes a film or membrane in contact with the agent and capable of releasing the agent from the ancillary device and into the patient.

16. The system of claim 8 wherein the ancillary device comprises a film or membrane capable of releasing a satiety inducing agent from the ancillary device and into the patient at a controlled rate.

17. The system of claim 8 wherein the ancillary device is structured to be capable of releasing a satiety inducing agent into the patient at a controlled rate.

18. The system of claim 1 wherein the band is structured to be capable of releasing a satiety inducing agent into the patient at a controlled rate.

20. The method of claim 18 wherein the agent is an agent selected from the group consisting of Glucagon-like peptide (GLP-1), Oxyntomodulin (OXM), Peptide YY (PYY), Pancreatic Polypeptide (PP), Insulin, Leptin, Gastrin, Ghrelin blocker, an inhibitors of DPP-IV, and Amylin.

21. The method of claim 18 wherein the bioerodible material is capable of releasing the agent into the patient at a controlled rate.

19. A method of inducing weight loss in a patient, the method comprising

implanting a gastric band device in a patient;

and

providing a composition, the composition comprising an active agent effective to induce weight loss and a bioerodible material combined with the agent, the agent being distributed in the bioerodible material and being effective, when released into the patient, to at least assist in inducing weight loss in the patient;

the composition being positioned between the gastric band and the stomach of the patient when the gastric band is positioned around the stomach of the patient.

22. A method of treating obesity or an obesity related condition comprising:

positioning a gastric band on the stomach of a patient; and

administering a satiety inducing agent to the patient while the gastric band is positioned on the stomach.

23. The method of claim 22 wherein the step of administering comprises dispensing the agent to one of the stomach, intestine, peritoneum, intra-peritoneal cavity, and abdomen of the patient.

24. The method of claim 22 wherein the step of administering comprises administering the agent subcutaneously to the patient.

25. The method of claim 22 wherein the step of administering comprises administering the agent directly to the central nervous system.

26. The method of claim 22 wherein the agent is administered as an inhalant.

27. The method of claim 22 wherein the step of administering comprises controlling a rate of release of the agent into the patient.

28. The method of claim 22 wherein the agent is selected from the group consisting of Glucagon-like peptide (GLP-1), Oxyntomodulin (OXM), Peptide YY (PYY), Pancreatic Polypeptide (PP), Insulin, Leptin, Gastrin, Ghrelin blocker, an inhibitors of DPP-IV, and Amylin.

29. The method of claim 22 wherein the step of administering comprises administering the agent at a controlled rate over a period of at least about six months.

30. The method of claim 22 wherein the step of administering comprises administering the agent at a controlled rate over a period of at least about one year.

31. The method of claim 22 wherein the step of administering comprises administering the agent at a controlled rate over a period of at least about three years.

32. The method of claim 22 wherein the step of administering comprises administering the agent at a controlled rate over a period of between about six months and about three years, the controlled rate including a period of dosage tapering.